NCT07787039 Supporting Treatment for Opioids and Recovery Capital (STORC) - R61 Phase
| NCT ID | NCT07787039 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Friends Research Institute, Inc. |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-09-26 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2026-09-26 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We are studying whether training an identified support person and providing patient navigation (i.e. a peer recovery specialist assisting you with finding the right support) after delivery can increase "recovery capital"-the resources that help people with opioid use disorder (OUD) stay in treatment and recover. This study will build upon the research team's prior work in conducting research among pregnant and parenting women with OUD. This project will be directed by the research team at Friends Research Institute in close collaboration with their research and clinical partners at the University of Pennsylvania in Philadelphia, PA. A two-phase study is proposed with an initial 1-year developmental phase (R61) that will develop and pilot test STORC to include support person training. A second 4-year phase (R33) will test STORC in a parallel, two-arm, randomized controlled trial design at two study sites.
Eligibility Criteria
Inclusion Criteria: * must be biological females * must be currently within 6 weeks postpartum * must be able to read, write, and speak English at a 6th-grade level * must be diagnosed and receiving treatment for, or willing to receive treatment for opioid use disorder at the PROUD clinic * must identify a support person who also consents to participate. Patient participants must identify prospective support persons in order to complete consent Exclusion Criteria: * pregnancy * planned discharge to a long-term inpatient care facility (e.g., hospice) * hospitalization for a suicide attempt * major mental health disorder that requires treatment before OAT can be considered * stillbirth or neonatal death of the index pregnancy/infant, as determined from the obstetric record.
Contact & Investigator
Karen Alexander
PRINCIPAL INVESTIGATOR
Friends Research Institute, Inc.
Frequently Asked Questions
Who can join the NCT07787039 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07787039 currently recruiting?
Yes, NCT07787039 is actively recruiting participants. Contact the research team at kalexander@friendsresearch.org for enrollment information.
Where is the NCT07787039 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07787039 clinical trial?
NCT07787039 is sponsored by Friends Research Institute, Inc.. The principal investigator is Karen Alexander at Friends Research Institute, Inc.. The trial plans to enroll 10 participants.